The trials, across 11 centres, also show that liquid cannabidiol - a derivative of cannabis - may have an adequate safety profile.
Researchers, led by the New York University Langone Medical Center, evaluated 162 children and young adults aged from one to 30 over 12 weeks. They were all treated...